Table 3 Characteristics and acute TBE manifestations in previously unvaccinated TBE cases, cases with vaccination breakthrough infections, and cases with incomplete TBE vaccination at 1–2 doses.
From: Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany
Age group | Unvaccinated cases | VBI cases | Cases with 1–2 doses | p-value | p-value |
|---|---|---|---|---|---|
n = 497a | n = 17a | n = 37a | VBI vs. unvaccinated | 1–2 doses vs. unvaccinated | |
n (%) | n (%) | n (%) | |||
2–13 years | 48 (9.7%) | 1 (5.9%) | 3 (8.1%) | 0.037 | 0.058 |
14–64 years | 345 (69.4%) | 8 (47.1%) | 32 (86.5%) | ||
≥ 65 years | 104 (20.9%) | 8 (47.1%) | 2 (5.4%) | ||
Demographics | |||||
Male | 314 (63.2%) | 9 (52.9%) | 23 (62.2%) | 0.390 | 0.902 |
≥ 1 comorbidityb | 193 (38.8%) | 12 (70.6%) | 17 (45.9%) | 0.009 | 0.393 |
Immunosuppression in exposure time | 13 (2.6%) | 1 (5.9%) | 0 (0.0%) | 0.128 | 0.500 |
Acute TBE severityc | |||||
Mild | 102 (20.5%) | 0 (0.0%) | 9 (24.3%) | < 0.001 | 0.255 |
Moderate | 306 (61.6%) | 6 (35.3%) | 18 (48.6%) | ||
Severe | 89 (17.9%) | 11 (64.7%) | 10 (27.0%) | ||
Clinical characteristics | |||||
Biphasic course | 197 (39.6%) | 10 (58.8%) | 21 (56.8%) | < 0.001 | < 0.001 |
Hospitalised | 443 (89.1%) | 17 (100.0%) | 33 (89.2%) | 0.151 | 0.992 |
Median hospital stay (days, range) | 10 (1–84) | 14 (6–90) | 10.5 (2–40) | – | – |
ICU admission | 54 (10.9%) | 8 (47.1%) | 6 (16.2%) | < 0.001 | 0.320 |
RANKIN score22 and interval between symptom onset and measuring RANKIN | |||||
Median interval (days, interquartile range) | 93 (66–144) | 96 (66–198) | 100 (76–177) | – | – |
0: No symptoms | 243 (50.8%) | 3 (20.0%) | 15 (42.9%) | < 0.001 | 0.629 |
1: No significant disability | 145 (30.3%) | 1 (6.7%) | 13 (37.1%) | ||
≥ 2: Slight disability, or worse | 90 (18.8%) | 10 (66.7%) | 7 (20.0%) | ||
